Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: Identification of regulatory cells

Journal of Immunology

Volumn 162, Issue 10, 1999, Pages 5757-5763

  Shi, Fu Dong ^a   Li, Hulun ^b   Wang, Huabing ^b   Bai, Xuefeng ^b,d   Van Der Meide, Peter H ^c   Link, Hans ^b   Ljunggren, Hans Gustaf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHOLINERGIC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INTRANASAL DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUPPRESSOR CELL;

ANIMALS; ANTIBODIES; ANTIGENS, CD4; ANTIGENS, CD8; AUTOANTIGENS; CYTOKINES; IMMUNE TOLERANCE; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NASAL MUCOSA; RECEPTORS, CHOLINERGIC; SPLEEN;

EID: 0033563161     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Whitacre, C. C., I. E. Gienapp, A. Meyer, K. L. Cox, and N. Javed. 1996. Treatment of autoimmune diseases by oral tolerance to autoantigens. Clin. Immunol. Immunopathol 80:31.
2. Weiner, H. L. 1997. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today 18:335.
3. Gaupp, S., H. P. Hartung, K. Toyka, and S. Jung. 1997. Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens. J. Neuroimmunol. 76:129.
4. Wang, Z. Y., J. Qiao, and H. Link. 1993. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44:209.
5. Okumura, S., K. McIntosh, and D. B. Drachman. 1994. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann. Neurol. 36:704.
6. Freiedman, A., and H. L. Weiner. 1994. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. USA 91:6688.
7. Critchfield, J. M., M. K. Racke, J. C. Zuniga-Pflucker, B. Cannella, C. S. Raine, J. Goverman, M. J. Lenardo. 1994. T cell deletion in high dose therapy of autoimmune encephalomyelitis. Science 263:1139.
8. Chen, Y., J. I. Inobe, R. Marks, P. Gonnella, V. K. Kuchroo, and H. L. Weiner. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376:177.
9. + cells mediated active suppression. J. Immunol. 155:910.
10. Liu, J., X. Bai, F. D. Shi, B. Xiao, H. Li, M. Levi, M. Mustafa, B. Wahren, and H. Link. 1998. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99. Int. Immunol. 10:1139.
11. Anderton, S. M., and D. C. Wraith. 1998. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur. J. Immunol. 28:1251.
12. Tian, J., M. A. Atkinson, M. Clare-Salzler, A. Herschenifeld, T. Forsthuber, P. V. Lehmann, and D. L. Kaufman. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183:1561.
13. Harrison, L. C., M. Dempsey-Collier, D. R. Kramer, and K. Takahashi. 1996. Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. 184:2167.
14. Staines, N. A., N. Harper, F. J. Ward, V. Malmström, R. Holmdahl, and S. Bansal. 1996. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103: 386.
15. Ma, C., G. Zhang, B. Xiao, J. Link, T. Olsson, and H. Link. 1995. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58:51.
16. Shi, F. D., X. Bai, B. Xiao, P. H. van der Meide, and H. Link. 1998. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis, and neuritis. J. Neurol. Sci. 155:1.
17. Li, H., F. D. Shi, X. Bai, Y. Huang, P. H. van der Meide, and H. Link. 1998. Nasal tolerance in experimental autoimmune myasthenia gravis: tolerance reversal by nasal administration of minute amount of IFN-γ Clin. Immunol. Immunopathol. 87:15.
18. Lindstrom J., B. Einarson, and S. Tzartos. 1981. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74:432.
19. Deibler, G. E., R. E. Martensson, and M. W. Kies. 1972. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 2:139.
20. Berman, P. W., and J. Patric. 1980. Experimental myasthenia gravis: a murine system. J. Exp. Med 151:204.
21. Christadoss, P., J. Lindstrom, S. Munro, and N. Talal. 1985. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlation with cellular, humoral, and clinical responses. J. Neuroimmunol. 8:29.
22. Macdonald, R. A., C. S. Hosking, C. L. Jones. 1988. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods 106: 191.
23. Shi, F. D., X. Bai, H. Li, Y. Huang, P. H. van der Meide, and H. Link. 1998. Nasal tolerance in experimental autoimmune myasthenia gravis: induction of protective tolerance in primed animals. Clin. Exp. Immunol. 111:506.
24. Dasch, J. R., D. R. Pace, W. Waegell, D. Ineaga, and L. Ellingsworth. 1989. Monoclonal antibodies recognizing TGF-β: bioactivity neutralization and TGF-β2 affinity purification. J. Immunol. 142:1536.
25. + T cells. J. Exp. Med. 183:2669.
26. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 184:349.
27. Drachman, D. B. 1994. Myasthenia gravis. N. Engl. J. Med 330:1797.
28. Link, H., O. Olsson, J. Sun, W. Wang, G. Andersson, H. P. Ekre, T. Brenner, O. Abrasky, and T. Olsson. 1991. Acetylcholine receptor reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87:2191.
29. Mosmann, T. R., and S. Sad. 1996. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol. Today 17:138.
30. Ma, C., G. Zhang, B. Xiao, T. Olsson, and H. Link. 1996. Cellular mRNA expression of IFN-γ, IL-4, and TGF-β in rats nasally tolerized against experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. 104:509.
31. + T cell clones derived from rats nasally tolerized against experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 89:196.
32. Karachunski, P. I., N. S. Ostlie, D. K. Okita, and B. M. Conti-Fine. 1997. Prevention of experimental autoimmune myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100:3027.
33. + T cell deficiency on experimental autoimmune myasthenia gravis pathogenesis. J. Immunol. 152:5330.
34. + T cells suppresses experimental autoimmune myasthenia gravis in Lewis rat. Eur. J. Immunol. 25:1191.
35. Paganelli, R., E. Scala, F. Aiuti, and M. Fiorilli. 1998. B-cell help by Tc2 cells. Immunol. Today 19:142.
36. Dedhia, V., E. Goluszko, B. Wu, C. Deng, and P. Christadoss. 1998. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 87:266.
37. Li, H., F. D. Shi, B. He, M. Bakheit, B. Wahren, A. Berglöf, K. Sandstedt, and H. Link. 1998. Experimental autoimmune myasthenia gravis in B cell-deficient mice. Int. Immunol. 10:1359.
38. Nakano, S., and A. G. Engel. 1993. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43:1167.
39. Morimoto, C., E. L. Reinberz, R. F. Todd, J. A. Distaso, and S. F. Schlossman. 1983. Generation of antigen-specific suppressor cells in vitro in man. J. Immunol. 131:1203.
40. + T lymphocytes. J. Immunol. 142: 784.
41. Vistica, B. P., N. P. Chanaud III, N. Felix, R. R. Caspi, L. V. Rizzo, R. B. Nussemblatt, and I. Gery. 1996. CD8 T cells are not essential for the induction of "low-dose" oral tolerance. Clin. Immunol. Immunopathol. 78:196.
42. Dick, A. D., Y. F. Cheng, A. McKinnon, J. Liversidge, and J. V. Forrester. 1993. Nasal administration of retina antigens suppresses the inflammatory responses in experimental allergic uveoretinis: a preliminary report of intranasal induction of tolerance with retina antigens. Br. J. Ophthalmol 77:171.
43. Brandtzaeg, P. 1996. History of oral tolerance and mucosal immunity. Ann. N. Y. Acad. Sci. 778:1.
44. + T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J. Exp. Med. 178:889.
45. Genain, C. P., K. Abel, N. Belmar, F. Villinger, D. P. Rosenberg, C. Linington, C. S. Raine, and S. L. Hauser. 1996. Late complications of immune deviation therapy in a nonhuman primate. Science 274:2054.
46. Blanas, E., F. R. Carbone, J. Allison, J. F. A. P. Miller, and W. R. Heath. 1997. Induction of autoimmune diabetes by oral feeding of autoantigen. Science 274:1707.
47. Balasa, B., C. Deng, J. Lee, L. M. Bradley, P. Christadoss, and N. Sarvetnick. 1997. IFN-γ is essential for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:385.
48. Wu, B., C. Deng, E. Goluszko, and P. Christadoss. 1997. Tolerance to a dominant epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. 159:3016.
49. Yang, B., K. R. McIntosh, and D. B. Drachman. 1998. How subtile differences in MHC class II affect the severity of experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 86:45.
50. Moiola, L., F. Galbiati, G. Mattino, S. Amadio, E. Brambilla, G. Comi, A. Vincent, L. M. E. Grimaldi, and L. Adorini. 1998. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28:2487.
51. Balasa, B., C. Deng, J. Lee. P. Christadoss, and N. Sarvetnick. 1998. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161:2856.